BC Extra | Sep 13, 2019
Company News

FDA panel backs Aimmune’s peanut allergy therapy, wants expanded REMS

Despite concerns over a new surrogate endpoint and increased risk of allergic reactions, the very thing the treatment is designed to diminish, an FDA advisory panel voted 7-2 in favor of the efficacy of Aimmune’s...
Items per page:
1 - 1 of 1